1Q23 Business Results
Business Growth with Portfolio Enhancement
ā More than one follow-up product will be launched every year in time for the expiration of original patents
ā Portfolio will be enhanced through the pipelines and its experience of biosimilar commercialization
CTHC's target market size in EU & the US
(Unit: USD bn)
CTHC's revenue & portfolio outlook
20.6
~122
+161%
----------
Note: The market size is as of 3Q22MAT
Source: IQVIA
53.7
+70%
91.3
'23(E)
'24(E)~
(Unit: KRW bn, ea)
12
1,628
1,805
1,972
Revenue
1,101
7
6
No. of
Portfolio
4
3
'19
'20
20
'21
'22
'26(E)
EU
US
2023(E)
Vegzelma
bevacizumab
Yuflyma
adalimumab
CT-P43
CT-P39
CT-P41
CT-P42
CT-P47
bStelara bXolair
bProlia bEylea bActemra
2024(E)
Remsima
SUBCUTANEOUS
2025(E)
2026(E)
Infliximab
CT-P41
CT-P39
CT-P47
bProlia bXolair
bActemra
CT-P43
CT-P42
bStelara bEylea
Note: Launching plan could be subjective to the approval
Investor Relations 2023 14
1Q23 Business Results Key Products
Plan & Vision
AppendixView entire presentation